Clinical
4 Ways to Guarantee your Trials Become More Patient-Centric
Could trials be at risk of being invalidated by rebellion from patients?
More Clinical Articles
Clinical
Risk Sharing Agreements on the American Horizon
US stakeholders are beginning to consider risk sharing agreements, but to what effect?
Clinical
Alzheimer’s: Can we save the world from a public health disaster?
Alzheimer’s disease is a ticking time bomb for public health around the world. If we don’t act now, it will single-handedly devastate global healthcare systems.
Clinical
Partnership: The Game Changer in Alzheimer’s Research
A unique public-private partnership aims to change the face of Alzheimer’s dementia research by avoiding the duplication of research efforts. Danielle Barron speaks to those involved to find out why this new approach may finally lead to effective treatments for the condition.
Clinical
Patient Centered Clinical Trials
As pharmaceutical companies compete to bring new drugs to market, there is an increasing emphasis on the need for patient centricity – to retain patient volunteers and produce quality data. We spoke to Duncan Cantor, Director of Communications, Boehringer Ingelheim, about the importance of patient centricity in clinical trials.
Clinical
Time to flourish
Failure is going to be part of the process with biosimilars, but for companies with an entrepreneurial spirit and a clear mindset, the rewards are also there...
Clinical
GSK Clinical Trial Questionnaire: Most Valuable Patient Initiative
A move towards greater patient centricity was behind GSK's desire to get systematic feedback from participants in clinical trials – and the company hopes its blueprint can be taken up by rivals.
Clinical
Engineering a Culture of Innovation Part 2: Social Contracts
Continuing the recent interview with Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential', we now look more closely at the elements of engineering a culture of innovation.
Clinical
Size Matters
Dr Robert Langer was the recent recipient of the Queen Elizabeth Prize in Engineering, for his groundbreaking research into controlled, targeted drug delivery. eyeforpharma unravels his past achievements, discusses his present research and offers his future vision of medicine.
Clinical
Right on target
US President Barack Obama recently pledged $215m for his precision medicine initiative. Danielle Barron discusses the future of precision medicine with InnVentis founder and CEO Thomas Wilckens, and examines the impact this will have on the current R&D environment.